Valitse alue, joka parhaiten vastaa sijaintiasi tai mieltymyksiäsi.
Tämä asetus hallitsee käyttöliittymän kieltä, mukaan lukien painikkeet, valikot ja kaikki sivuston tekstit. Valitse haluamasi kieli parhaan selauskokemuksen saamiseksi.
Valitse kielet työpaikkailmoituksille, jotka haluat nähdä. Tämä asetus määrittää, mitkä työpaikkailmoitukset näytetään sinulle.
The Nuclear Medicine and Molecular Imaging research group (KU Leuven – UZ Leuven) is a multidisciplinary team of doctors, physicists/engineers and pharmacists/chemists. Together with our clinical partners, we develop and implement innovative PET technologies for the study of brain disorders at the molecular level. The research group has a strong international reputation in neuroimaging and neurodegenerative disorders and, since 2025, has been the first centre in Europe to have an ultra-high-resolution NeuroEXPLORER PET scanner.
Neuroinflammation plays a key role in numerous neurological disorders. This PhD project forms part of a first-in-human study of a new PET radiotracer as a promising biomarker of microglial activation and neuroinflammation.
The project comprises:
· Biodistribution, dosimetry and kinetic modelling of the new radioligand in healthy volunteers, patients with Alzheimer’s disease (AD) and multiple sclerosis (MS).
· Application of ultra-high-resolution NeuroEXPLORER PET for imaging neuroinflammatory processes in the brain, with a focus on neuroinflammation in healthy ageing.
· Comparison between patients with AD or MS and age-matched healthy controls.
· Integration of PET data with MRI, clinical data, cognitive assessments and biological markers.
· Application of advanced analytical methods for brain imaging, kinetic modelling and voxel-based statistics.
· Active involvement in the recruitment, screening and follow-up of healthy volunteers, AD and MS patients within the clinical trial programme.
By utilising a completely new neuroinflammation target and a unique imaging infrastructure, this project aims to contribute to a better understanding of neuroinflammation in healthy ageing and in the disease process in AD and MS, as well as to the development of a new biomarker for diagnosis and treatment evaluation.
For more information please contact Prof. dr. Koen Van Laere, mail: [email protected] or dr. Greet Vanderlinden, mail: [email protected].
KU Leuven strives for an inclusive, respectful and socially safe environment. We embrace diversity among individuals and groups as an asset. Open dialogue and differences in perspective are essential for an ambitious research and educational environment. In our commitment to equal opportunity, we recognize the consequences of historical inequalities. We do not accept any form of discrimination based on, but not limited to, gender identity and expression, sexual orientation, age, ethnic or national background, skin colour, religious and philosophical diversity, neurodivergence, employment disability, health, or socioeconomic status. For questions about accessibility or support offered, we are happy to assist you at this email address.
KU Leuven is an autonomous university. It was founded in 1425. It was born of and has grown within the Catholic tradition.
Käy työnantajan sivulla